Similar articles for PMID: 26637844

Year	Number of Results
2005	1
2007	2
2008	2
2009	3
2010	3
2011	2
2012	15
2013	21
2014	14
2015	25
2016	30
2017	29
2018	30
2019	20
2020	26
2021	25
2022	39
2023	17
2024	0

1

Long-term BCR-ABL1 Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia.

Pinilla-Ibarz J, Sweet K, Emole J, Fradley M. Pinilla-Ibarz J, et al. Anticancer Res. 2015 Dec;35(12):6355-64. Anticancer Res. 2015. PMID: 26637844 Review.

2

Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors.

Pietarinen PO, Eide CA, Ayuda-Durán P, Potdar S, Kuusanmäki H, Andersson EI, Mpindi JP, Pemovska T, Kontro M, Heckman CA, Kallioniemi O, Wennerberg K, Hjorth-Hansen H, Druker BJ, Enserink JM, Tyner JW, Mustjoki S, Porkka K. Pietarinen PO, et al. Oncotarget. 2017 Apr 4;8(14):22606-22615. doi: 10.18632/oncotarget.15146. Oncotarget. 2017. PMID: 28186983 Free PMC article.

3

BCR-ABL1 kinase domain mutation analysis in an Irish cohort of chronic myeloid leukemia patients.

McCarron SL, O'Connor LM, Langabeer SE, Conneally E. McCarron SL, et al. Genet Test Mol Biomarkers. 2013 Feb;17(2):170-3. doi: 10.1089/gtmb.2012.0272. Epub 2013 Jan 5. Genet Test Mol Biomarkers. 2013. PMID: 23289634

4

Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy.

Ferri C, Bianchini M, Bengió R, Larripa I. Ferri C, et al. Blood Cells Mol Dis. 2014 Feb-Mar;52(2-3):121-5. doi: 10.1016/j.bcmd.2013.09.002. Epub 2013 Oct 3. Blood Cells Mol Dis. 2014. PMID: 24091144

5

Tyrosine kinase inhibitor therapy in chronic myeloid leukemia: update on key adverse events.

Carneiro BA, Kaplan JB, Giles FJ. Carneiro BA, et al. Expert Rev Hematol. 2015 Aug;8(4):457-79. doi: 10.1586/17474086.2015.1041910. Epub 2015 May 4. Expert Rev Hematol. 2015. PMID: 25938861 Review.

6

Target spectrum of the BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia.

Lee H, Basso IN, Kim DDH. Lee H, et al. Int J Hematol. 2021 May;113(5):632-641. doi: 10.1007/s12185-021-03126-6. Epub 2021 Mar 27. Int J Hematol. 2021. PMID: 33772728 Review.

7

Comparison of molecular responses based on BCR-ABL1% (IS) results from an in-house TaqMan-based qPCR versus Xpert(®) assay in CML patients on tyrosine kinase inhibitor therapy.

Boeckx N, Laer CV, Roover JD, Wilmsen B, Bruyninckx K, Pauwels S. Boeckx N, et al. Acta Clin Belg. 2015 Aug;70(4):237-43. doi: 10.1179/2295333715Y.0000000009. Epub 2015 Jul 13. Acta Clin Belg. 2015. PMID: 26166681

8

BCR-ABL1 tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.

Cuellar S, Vozniak M, Rhodes J, Forcello N, Olszta D. Cuellar S, et al. J Oncol Pharm Pract. 2018 Sep;24(6):433-452. doi: 10.1177/1078155217710553. Epub 2017 Jun 4. J Oncol Pharm Pract. 2018. PMID: 28580869 Free PMC article. Review.

9

Early BCR-ABL1 Transcript Decline after 1 Month of Tyrosine Kinase Inhibitor Therapy as an Indicator for Treatment Response in Chronic Myeloid Leukemia.

El Missiry M, Hjorth-Hansen H, Richter J, Olson-Strömberg U, Stenke L, Porkka K, Kreutzman A, Mustjoki S. El Missiry M, et al. PLoS One. 2017 Jan 30;12(1):e0171041. doi: 10.1371/journal.pone.0171041. eCollection 2017. PLoS One. 2017. PMID: 28135325 Free PMC article.

10

WHO 2016 Definition of Chronic Myeloid Leukemia and Tyrosine Kinase Inhibitors.

Haznedaroğlu İC, Kuzu I, İlhan O. Haznedaroğlu İC, et al. Turk J Haematol. 2020 Feb 20;37(1):42-47. doi: 10.4274/tjh.galenos.2019.2019.0241. Epub 2019 Oct 15. Turk J Haematol. 2020. PMID: 31612694 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

261 results

Results by year